Racura Oncology LtdASX: RAC

Race Receives $4.0m R&D Tax Refund for Financial Year 2023

· Issued by Racura Oncology Ltd

Filed with ASX · · 2 pages · English

Summary by 6ix AI

The refund, amounting to a substantial sum, is part of the Federal Government’s R&D Tax Incentive scheme aimed at encouraging investment in innovation. The CEO highlighted the importance of this funding in advancing the clinical development of their lead asset, bisantrene, in the upcoming year.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Racura Oncology Ltd on 6ix

Earlier from Racura Oncology

Later from Racura Oncology

All Racura Oncology news releases